Country: South Africa
Language: English
Source: South African Health Products Regulatory Authority (SAHPRA)
Lennon
PLENISH-K®Tablets SCHEDULING STATUS: S2 PROPRIETARY NAME (and dosage form): PLENISH-K ® Tablets COMPOSITION: Each tablet contains 600 mg potassium chloride in a slow release core. PHARMACOLOGICAL CLASSIFICATION: A 24 Mineral substitutes, electrolytes. PHARMACOLOGICAL ACTION: The tablets are especially formulated in a slow-release core to minimise the possibility of gastro-intestinal irritation which may arise from a localised high concentration of potassium in the gut. Potassium is of fundamental importance in the ionic exchange of cellular metabolism. Potassium is the predominating cation of the intracellular fluid and erythrocytes. INDICATIONS: Potassium chloride tablets are used in the treatment of potassium deficiency which may arise due to diuretic therapy, hypochloraemic alkalosis, diabetic acidosis or steroid therapy. There is no proof that the dosage of potassium chloride contained in this medicine will necessarily serve to prevent a meaningful loss of potassium or normalise an existing shortage of potassium. CONTRA-INDICATIONS: Hyperkalaemia, ulceration of the bowel. DOSAGE AND DIRECTIONS FOR USE: As an adjunct to diuretic therapy: 2 to 6 tablets daily. SIDE-EFFECTS AND SPECIAL PRECAUTIONS: Nausea, vomiting, diarrhoea and abdominal cramps may rarely occur. Intestinal ulceration has been reported. Caution should be observed in treating patients with renal or adrenal insufficiency, acute dehydration or heat cramp. In the presence of reduced renal function hyperkalaemia may be produced. KNOWN SYMPTOMS OF OVERDOSAGE AND PARTICULARS OF ITS TREATMENT: Excessive doses may cause hyperkalaemia with paraesthesia of the extremities, mental confusion, paralysis, hypotension, cardiac arrhythmias, heart block and cardiac arrest. Treatment of overdosage is symptomatic. IDENTIFICATION: White, deep biconvex Read the complete document